


A blood cancer supportive care trial



Comparing immunoglobulin and antibiotics to prevent infection in patients with blood cancers

SC.30 | NCT07202052

What is the purpose of this trial?

The purpose of this study is to compare different approaches to preventing infections in people with blood cancers who have low antibody levels.



Why is this trial important?

Patients with blood cancers often develop low levels of antibodies that can lead to an increased chance of developing an infection. These infections can cause serious illness, which may require being admitted to hospital. To help prevent this, many patients receive immunoglobulin replacement therapy (IgRT). However, there is limited evidence on when to start or stop IgRT, what dose to use, and if antibiotics can be used instead. This study may help doctors who treat patients with blood diseases in the future to understand which treatment to prescribe to prevent serious infections.

Who can participate in this study?



Patients with blood cancer who have low levels of certain antibodies (immunoglobulins) in the blood may be able to participate. Your treating doctor will check your eligibility to participate in this study. You will need to undergo screening assessments to find out if it is safe for you to be involved in the study.



SHARE THIS SUMMARY WITH YOUR HEALTH CARE TEAM
TO SEE IF THIS TRIAL IS A GOOD OPTION FOR YOU.

What are the risks?



If you choose to take part in this study, there is a risk that the study approach may not be as good as the standard treatment. While all study treatments are already being used, participation in the study may involve some risks, including:

- **Risk of infection:** If IgRT is stopped, someone with a weak immune system could get sick more easily, for example, by catching pneumonia.
- **Immunoglobulin therapy side effects:** Staying on IgRT can sometimes cause reactions during treatment, like getting a fever and chills, serious allergic reactions and/or flu-like symptoms.
- **Antibiotic use risks:** Antibiotics can sometimes cause nausea, diarrhea and allergic reactions. Using antibiotics too often can also make infections harder to treat later (antibiotic resistance).

What can I expect?

If you choose to take part in this study, you will be randomly placed in a treatment group testing an approach to preventing infections. In this study, you will also be asked to complete a few questionnaires and diaries at different times, depending on the group you're in.

How can I find out more or join the study?



Talk to your cancer doctor if you are considering joining this study. You can share summaries like this with them and ask if they think joining the trial may be a good option for you.

Before you join this study, you will be asked to review an *Informed Consent* document which will tell you more about why the research is being done and your role as a participant. You will have an opportunity to discuss anything that is not clear and ask any questions you have.

Joining this study is entirely up to you and you can decide to leave at any time without giving a reason. Your decision to join or leave the trial will not affect your standard medical care.

The **SC.30 study** is currently enrolling patients at cancer centres in Canada. For more information and a list of participating cancer centres please visit:

<https://clinicaltrials.gov/study/NCT07202052?term=rational&cond=hematology&rank=2>

or

<https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=387826&isReview=true>

CLINICAL TRIAL SPONSOR

Canadian Cancer
Trials Group



Groupe canadien
des essais sur le cancer